We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Influence of the Lymph Node Ratio on Lymph Node Metastasis-positive Gastric Cancer Patients Who Receive Curative Treatment.
- Authors
TORU AOYAMA; KESIKEU KOMORI; AYAKO TAMAGAWA; MASATO NAKAZANO; KENTARO HARA; ITARU HASHIMOTO; HIROSHI TAMAGAWA; KENKI SEGAMI; YUKIO MAEZAWA; KAZUKI KANO; TAKASHI OSHIMA; NORIO YUKAWA; YASUSHI RINO
- Abstract
Background/Aim: The present study investigated the clinical impact of the lymph node ratio (LNR) on overall survival (OS) and recurrence-free survival (RFS) in cancer patients with lymph node metastasis who received curative treatment. Patients and Methods: Eighty-six patients who received curative surgery for gastric cancer between 2000 and 2015, and in whom lymph node metastasis was pathologically confirmed, were included in this study. The LNR was defined as the ratio of the number of metastatic lymph nodes to the total number of harvested lymph nodes. Results: A lymph node ratio of 0.23 was considered the optimal cutoff point for classification according to OS. Statistically significant differences were observed in the 3- and 5-year OS rates and 3- and 5-year RFS rates. The 3- year and 5-year OS rates in the LNR <0.23 group were 57.6% and 57.6%, respectively, whereas those in the LNR ≥0.23 group were 33.0% and 0% (p<0.001). The 3-year and 5-year RFS rates in the LNR <0.23 group were 45.9% and 43.6%, respectively, whereas those in the LNR >0.23 group were 25.2% and 0% (p=0.002). Regarding the site of first relapse, the incidence rates of peritoneal and lymph node metastasis in the LNR >0.23 group were significantly different in comparison to the LNR <0.23 group. Conclusion: A high LNR was associated with significantly worse OS and RFS in patients who received curative treatment for gastric cancer. The lymph node metastasis status should be utilized in the development of treatment strategies for gastric cancer.
- Subjects
LYMPH node cancer; STOMACH cancer; CURATIVE medicine; OVERALL survival; PROGRESSION-free survival
- Publication
In Vivo, 2022, Vol 36, Issue 2, p994
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12792